1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: ESC/ESH Task Force for the Management of Arterial Hypertension. Journal of Hypertension. 2018;36(12):2284–309. DOI: 10.1097/HJH.0000000000001961
2. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan MJ et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. The Lancet. 2017;389(10064):37–55. DOI: 10.1016/S0140-6736(16)31919-5
3. Quan H, Chen G, Walker RL, Wielgosz A, Dai S, Tu K et al. Incidence, cardiovascular complications and mortality of hypertension by sex and ethnicity. Heart. 2013;99(10):715–21. DOI: 10.1136/heartjnl-2012-303152
4. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix Metalloproteinases: Inflammatory Regulators of Cell Behaviors in Vascular Formation and Remodeling. Mediators of Inflammation. 2013;2013:1–14. DOI: 10.1155/2013/928315
5. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Critical Reviews in Biochemistry and Molecular Biology. 2007;42(3):113–85. DOI: 10.1080/10409230701340019
6. Moskalenko M.I. The involvement of genes of matrix metalloproteinases in the development of arterial hypertension and its complication (review). Research Result. Medicine and Pharmacy. 2018;4(1):53–69.. DOI: 10.18413/2313-8955-2018-4-1-53-69
7. Rudyh N.A., Sirotina S.S. Genetic interrelations of Russian and Ukrainian populations of Belgorod region. Research Result. Medicine and Pharmacy. 2015;1 (3):72–9.. DOI: 10.18413/2313-8955-2015-1-3-72-79
8. Sorokina I.N., Rudykh N.A., Bezmenova I.N., Polyakova I.S. Population genetic characteristics and genetic epidemiological research of candidate genes associations with multifactorial diseases. Research Results in Biomedicine. 2018;4(4):20–30.. DOI: 10.18413/2313-8955-2018-4-4-0-3
9. Britov A. N., Pozdnyakov Yu. M., Volkova E. G., Drapkina O. M., Еганян Р. А., Kislyak O. A. et al. National recommendations of cardiovascular prevention. Cardiovascular Therapy and Prevention. 2011;10 (6 S2):2–64.
10. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M et al. Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology. 2013;62(25):D42–50. DOI: 10.1016/j.jacc.2013.10.032
11. Ponomarenko I.V. Selection of polymorphic loci for association analysis in genetic-epidemiological studies. Research Result. Medicine and Pharmacy. 2018;4(2):40–54.. DOI: 10.18413/2313-8955-2018-4-2-0-5
12. Pradhan-Palikhe P, Pussinen PJ, Vikatmaa P, Palikhe A, Kivimäki AS, Lepäntalo M et al. Single nucleotide polymorphism – 799C/T in matrix metalloproteinase-8 promoter region in arterial disease. Innate Immunity. 2012;18(3):511–7. DOI: 10.1177/1753425911423852
13. Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A et al. Genetic polymorphisms of MMP1, MMP3 and MMP7gene promoter and risk of colorectal adenoma. BMC Cancer. 2006;6(1):270. DOI: 10.1186/1471-2407-6-270
14. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Research. 2016;44(D1):D877–81. DOI: 10.1093/nar/gkv1340
15. GTEx Consortium. Genetic effects on gene expression across human tissues. Nature. 2017;550(7675):204–13. DOI: 10.1038/nature24277
16. Hu W, Ye Y, Yin Y, Sang P, Li L, Wang J et al. Association of matrix metalloprotease 1, 3, and 12 polymorphisms with rheumatic heart disease in a Chinese Han population. BMC Medical Genetics. 2018;19(1):27. DOI: 10.1186/s12881-018-0538-4
17. Beilby JP, Chapman CML, Palmer LJ, McQuillan BM, Thompson PL, Hung J. Stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism is associated with blood pressure in a community population. Journal of Hypertension. 2005;23(3):537–42. PMID: 15716694
18. Sakowicz A, Fendler W, Lelonek M, Sakowicz B, Pietrucha T. Genetic Polymorphisms and the Risk of Myocardial Infarction in Patients Under 45 Years of Age. Biochemical Genetics. 2013;51(3–4):230–42. DOI: 10.1007/s10528-012-9558-5
19. Jormsjö S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P. Allele-Specific Regulation of Matrix Metalloproteinase-7 Promoter Activity Is Associated with Coronary Artery Luminal Dimensions Among Hypercholesterolemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21(11):1834–9. DOI: 10.1161/hq1101.098229
20. Mishra A, Srivastava A, Mittal T, Garg N, Mittal B. Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clinica Chimica Acta. 2012;413(19–20):1668–74. DOI: 10.1016/j.cca.2012.05.012
21. Mallat Z. Matrix Metalloproteinase-8 and the Regulation of Blood Pressure, Vascular Inflammation, and Atherosclerotic Lesion Growth. Circulation Research. 2009;105(9):827–9. DOI: 10.1161/CIRCRESAHA.109.208595
22. Hoseini SM, Kalantari A, Afarideh M, Noshad S, Behdadnia A, Nakhjavani M et al. Evaluation of plasma MMP8, MMP9 and TIMP1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case–control study. Metabolism. 2015;64(4):527–38. DOI: 10.1016/j.metabol.2014.12.009
23. Lin T-H, Yang S-F, Chiu C-C, Su H-M, Wang C-L, Voon W-C et al. Matrix metalloproteinase-1 mitral expression and – 1607 1G/2G gene promoter polymorphism in mitral chordae tendinae rupture. Translational Research. 2013;161(5):406–13. DOI: 10.1016/j.trsl.2012.10.002
24. Zhang G, Li W, Guo Y, Li D, Liu Y, Xu S. MMP Gene Polymorphisms, MMP1 -1607 1G/2G, -519 A/G, and MMP12 -82 A/G, and Ischemic Stroke: A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases. 2018;27(1):140–52. DOI: 10.1016/j.jstrokecerebrovasdis.2017.08.021
25. Velho FM, Cohen CR, Santos KG, Silvello D, Martinelli N, Biolo A et al. Polymorphisms of Matrix Metalloproteinases in Systolic Heart Failure: Role on Disease Susceptibility, Phenotypic Characteristics, and Prognosis. Journal of Cardiac Failure. 2011;17(2):115–21. DOI: 10.1016/j.cardfail.2010.09.017
26. Djurić T, Živković M, Stanković A, Mečanin S, Alavantić D. Endothelial NOS G894 T and MMP3 5A/6A gene polymorphisms and hypertension in Serbian population. Journal of Clinical Laboratory Analysis. 2005;19(6):241–6. DOI: 10.1002/jcla.20085
27. Giannakos E, Vardali E, Bartekova M, Fogarassyova M, Barancik M, Radosinska J. Changes in activities of circulating MMP2 and MMP9 in patients suffering from heart failure in relation to gender, hypertension and treatment: a cross-sectional study. Physiological Research. 2016;65(Suppl 1):S149-152. PMID: 27643937
28. Alehagen U, Olsen RS, Länne T, Matussek A, Wågsäter D. PDGF-D gene polymorphism is associated with increased cardiovascular mortality in elderly men. BMC Medical Genetics. 2016;17(1):62. DOI: 10.1186/s12881-016-0325-z
29. Gammelmark A, Nielsen MS, Lundbye-Christensen S, Tjønneland A, Schmidt EB, Overvad K. Common Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Incident Myocardial Infarction: A Danish Case-Cohort Study. PLOS ONE. 2016;11(11):e0167217. DOI: 10.1371/journal.pone.0167217
30. Azarova Yu.E., Klyosova E.Yu., Konoplya A.I. The role of polymorphisms of glutamate-cysteine ligase in type 2 diabetes mellitus susceptibility in Kursk population. Научный Результат. Медицина И Фармация. 2018;4 (1):39–52.. DOI: 10.18413/2313-8955-2018-4-1-39-52